What is the current valuation of the US blepharitis market in 2024?

The overall market valuation was $132.3 Million in 2024. Read More

What is the projected market valuation for the US blepharitis market by 2035?

The projected valuation for 2035 is $238.61 Million. Read More

What is the expected CAGR for the US blepharitis market from 2025 to 2035?

The expected CAGR during the forecast period 2025 - 2035 is 5.51%. Read More

Which companies are the key players in the US blepharitis market?

Key players include Allergan, Bausch Health, Santen Pharmaceutical, Novartis, Johnson & Johnson, Alcon, Ocular Therapeutix, and Eyevance Pharmaceuticals. Read More

What are the main types of blepharitis and their market valuations?

Anterior Blepharitis was valued at $40.0 - $75.0 Million, Posterior Blepharitis at $50.0 - $100.0 Million, and Mixed Blepharitis at $42.3 - $63.61 Million. Read More

What treatment segments are available for blepharitis and their valuations?

Eye Cleansers were valued at $40.0 - $70.0 Million, Artificial Tears at $50.0 - $90.0 Million, and Antibiotic Therapy at $42.3 - $78.61 Million. Read More

How is the diagnosis of blepharitis segmented in the market?

Diagnosis segments include Physical Examination valued at $40.0 - $72.0 Million, Comprehensive Eye Examination at $60.0 - $110.0 Million, and Others at $32.3 - $56.61 Million. Read More

What are the end-user segments for blepharitis treatment?

End-user segments include Specialty Centers valued at $30.69 - $55.56 Million, Hospitals at $66.15 - $121.56 Million, and Others at $35.46 - $61.49 Million. Read More

What trends are observed in the treatment of blepharitis?

The treatment segment shows a growing interest in Artificial Tears, which are projected to reach $90.0 Million by 2035. Read More

How does the market for blepharitis compare between 2024 and 2035?

The market is expected to grow from $132.3 Million in 2024 to $238.61 Million by 2035, indicating robust growth. Read More

US Blepharitis Market

ID: MRFR/Pharma/18338-HCR 100 Pages Vikita Thakur Last Updated: September 10, 2026

US Blepharitis Market Research Report By Type (Anterior Blepharitis, Posterior Blepharitis, Mixed Blepharitis), By Treatment (Eye Cleansers, Antibiotic Therapy), By Diagnosis (Physical Examination) and By End User (Hospitals, Specialty Centers) - Growth & Industry Forecast 2025 To 2035

US Blepharitis Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)5.51%

2024 Market Size$ 132.3 Million

2025 Market Size$ 139.59 Million

2035 Market Size$ 238.61 Million

Key Players

Allergan

Bausch Health

Santen Pharmaceutical

Novartis

Johnson & Johnson

Alcon

Trends

Rising Awareness of Eye Health
Technological Advancements in Treatment
Personalized Treatment Approaches

Opportunities

Rising Geriatric Population
Increasing Prevalence of Blepharitis
Advancements in Diagnostic Techniques

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1. 1.1 EXECUTIVE SUMMARY
  1. 1.1.1 Market Overview
  2. 1.1.2 Key Findings
  3. 1.1.3 Market Segmentation
  4. 1.1.4 Competitive Landscape
  5. 1.1.5 Challenges and Opportunities
  6. 1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
1. 2.1 MARKET INTRODUCTION
  1. 2.1.1 Definition
  2. 2.1.2 Scope of the study
    1. 2.1.2.1 Research Objective
    2. 2.1.2.2 Assumption
    3. 2.1.2.3 Limitations
2. 2.2 RESEARCH METHODOLOGY
  1. 2.2.1 Overview
  2. 2.2.2 Data Mining
  3. 2.2.3 Secondary Research
  4. 2.2.4 Primary Research
    1. 2.2.4.1 Primary Interviews and Information Gathering Process
    2. 2.2.4.2 Breakdown of Primary Respondents
  5. 2.2.5 Forecasting Model
  6. 2.2.6 Market Size Estimation
    1. 2.2.6.1 Bottom-Up Approach
    2. 2.2.6.2 Top-Down Approach
  7. 2.2.7 Data Triangulation
  8. 2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
1. 3.1 MARKET DYNAMICS
  1. 3.1.1 Overview
  2. 3.1.2 Drivers
  3. 3.1.3 Restraints
  4. 3.1.4 Opportunities
2. 3.2 MARKET FACTOR ANALYSIS
  1. 3.2.1 Value chain Analysis
  2. 3.2.2 Porter's Five Forces Analysis
    1. 3.2.2.1 Bargaining Power of Suppliers
    2. 3.2.2.2 Bargaining Power of Buyers
    3. 3.2.2.3 Threat of New Entrants
    4. 3.2.2.4 Threat of Substitutes
    5. 3.2.2.5 Intensity of Rivalry
  3. 3.2.3 COVID-19 Impact Analysis
    1. 3.2.3.1 Market Impact Analysis
    2. 3.2.3.2 Regional Impact
    3. 3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
1. 4.1 Industrial Automation & Equipment, BY Type (USD Million)
  1. 4.1.1 Anterior Blepharitis
  2. 4.1.2 Posterior Blepharitis
  3. 4.1.3 Mixed Blepharitis
2. 4.2 Industrial Automation & Equipment, BY Treatment (USD Million)
  1. 4.2.1 Eye Cleansers
  2. 4.2.2 Artificial Tears
  3. 4.2.3 Antibiotic Therapy
3. 4.3 Industrial Automation & Equipment, BY Diagnosis (USD Million)
  1. 4.3.1 Physical Examination
  2. 4.3.2 Comprehensive Eye Examination
  3. 4.3.3 Others
4. 4.4 Industrial Automation & Equipment, BY End-user (USD Million)
  1. 4.4.1 Specialty Centers
  2. 4.4.2 Hospitals
  3. 4.4.3 Others
5 SECTION V: COMPETITIVE ANALYSIS
1. 5.1 Competitive Landscape
  1. 5.1.1 Overview
  2. 5.1.2 Competitive Analysis
  3. 5.1.3 Market share Analysis
  4. 5.1.4 Major Growth Strategy in the Industrial Automation & Equipment
  5. 5.1.5 Competitive Benchmarking
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Industrial Automation & Equipment
  7. 5.1.7 Key developments and growth strategies
    1. 5.1.7.1 New Product Launch/Service Deployment
    2. 5.1.7.2 Merger & Acquisitions
    3. 5.1.7.3 Joint Ventures
  8. 5.1.8 Major Players Financial Matrix
    1. 5.1.8.1 Sales and Operating Income
    2. 5.1.8.2 Major Players R&D Expenditure. 2023
2. 5.2 Company Profiles
  1. 5.2.1 Allergan (IE)
    1. 5.2.1.1 Financial Overview
    2. 5.2.1.2 Products Offered
    3. 5.2.1.3 Key Developments
    4. 5.2.1.4 SWOT Analysis
    5. 5.2.1.5 Key Strategies
  2. 5.2.2 Bausch Health (CA)
    1. 5.2.2.1 Financial Overview
    2. 5.2.2.2 Products Offered
    3. 5.2.2.3 Key Developments
    4. 5.2.2.4 SWOT Analysis
    5. 5.2.2.5 Key Strategies
  3. 5.2.3 Santen Pharmaceutical (JP)
    1. 5.2.3.1 Financial Overview
    2. 5.2.3.2 Products Offered
    3. 5.2.3.3 Key Developments
    4. 5.2.3.4 SWOT Analysis
    5. 5.2.3.5 Key Strategies
  4. 5.2.4 Novartis (CH)
    1. 5.2.4.1 Financial Overview
    2. 5.2.4.2 Products Offered
    3. 5.2.4.3 Key Developments
    4. 5.2.4.4 SWOT Analysis
    5. 5.2.4.5 Key Strategies
  5. 5.2.5 Johnson & Johnson (US)
    1. 5.2.5.1 Financial Overview
    2. 5.2.5.2 Products Offered
    3. 5.2.5.3 Key Developments
    4. 5.2.5.4 SWOT Analysis
    5. 5.2.5.5 Key Strategies
  6. 5.2.6 Alcon (CH)
    1. 5.2.6.1 Financial Overview
    2. 5.2.6.2 Products Offered
    3. 5.2.6.3 Key Developments
    4. 5.2.6.4 SWOT Analysis
    5. 5.2.6.5 Key Strategies
  7. 5.2.7 Ocular Therapeutix (US)
    1. 5.2.7.1 Financial Overview
    2. 5.2.7.2 Products Offered
    3. 5.2.7.3 Key Developments
    4. 5.2.7.4 SWOT Analysis
    5. 5.2.7.5 Key Strategies
  8. 5.2.8 Eyevance Pharmaceuticals (US)
    1. 5.2.8.1 Financial Overview
    2. 5.2.8.2 Products Offered
    3. 5.2.8.3 Key Developments
    4. 5.2.8.4 SWOT Analysis
    5. 5.2.8.5 Key Strategies
3. 5.3 Appendix
  1. 5.3.1 References
  2. 5.3.2 Related Reports
6 LIST OF FIGURES
1. 6.1 MARKET SYNOPSIS
2. 6.2 US MARKET ANALYSIS BY TYPE
3. 6.3 US MARKET ANALYSIS BY TREATMENT
4. 6.4 US MARKET ANALYSIS BY DIAGNOSIS
5. 6.5 US MARKET ANALYSIS BY END-USER
6. 6.6 KEY BUYING CRITERIA OF INDUSTRIAL AUTOMATION & EQUIPMENT
7. 6.7 RESEARCH PROCESS OF MRFR
8. 6.8 DRO ANALYSIS OF INDUSTRIAL AUTOMATION & EQUIPMENT
9. 6.9 DRIVERS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
10. 6.10 RESTRAINTS IMPACT ANALYSIS: INDUSTRIAL AUTOMATION & EQUIPMENT
11. 6.11 SUPPLY / VALUE CHAIN: INDUSTRIAL AUTOMATION & EQUIPMENT
12. 6.12 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 (% SHARE)
13. 6.13 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TYPE, 2024 TO 2035 (USD Million)
14. 6.14 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT, 2024 (% SHARE)
15. 6.15 INDUSTRIAL AUTOMATION & EQUIPMENT, BY TREATMENT, 2024 TO 2035 (USD Million)
16. 6.16 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS, 2024 (% SHARE)
17. 6.17 INDUSTRIAL AUTOMATION & EQUIPMENT, BY DIAGNOSIS, 2024 TO 2035 (USD Million)
18. 6.18 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END-USER, 2024 (% SHARE)
19. 6.19 INDUSTRIAL AUTOMATION & EQUIPMENT, BY END-USER, 2024 TO 2035 (USD Million)
20. 6.20 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
1. 7.1 LIST OF ASSUMPTIONS
7.1.1
1. 7.2 US MARKET SIZE ESTIMATES; FORECAST
  1. 7.2.1 BY TYPE, 2025-2035 (USD Million)
  2. 7.2.2 BY TREATMENT, 2025-2035 (USD Million)
  3. 7.2.3 BY DIAGNOSIS, 2025-2035 (USD Million)
  4. 7.2.4 BY END-USER, 2025-2035 (USD Million)
2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.3.1
1. 7.4 ACQUISITION/PARTNERSHIP
7.4.1

Certified Researchers

Enquiry

Customize Report

US Blepharitis Market Segmentation

US Blepharitis Market By Type (USD Million, 2025-2035)

Anterior Blepharitis
Posterior Blepharitis
Mixed Blepharitis

US Blepharitis Market By Treatment (USD Million, 2025-2035)

Eye Cleansers
Artificial Tears
Antibiotic Therapy

US Blepharitis Market By Diagnosis (USD Million, 2025-2035)

Physical Examination
Comprehensive Eye Examination
Others

US Blepharitis Market By End-user (USD Million, 2025-2035)

Specialty Centers
Hospitals
Others

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”